Scott M. Giacobello net worth and biography

Scott Giacobello Biography and Net Worth

Prior to joining the Company in 2021, Mr. Giacobello held key financial and operational leadership roles in commercial-stage growth companies. As Chief Financial Officer at GW Pharmaceuticals, he played a pivotal role in expanding US operations and preparing for commercial launch, leading the Company's financial strategy and raising more than $620 million ahead of its acquisition by Jazz Pharmaceuticals in 2021. Previously he served as the Chief Financial Officer of Chase Pharmaceuticals until their acquisition by Allergan, where he also held executive roles in corporate finance and global research and development. Mr. Giacobello holds a Bachelor’s in Business Administration (BBA) in Accountancy from the University of Notre Dame.

What is Scott M. Giacobello's net worth?: The estimated net worth of Scott M. Giacobello is at least $1.12 million as of April 16th, 2026. Mr. Giacobello owns 295,224 shares of Whitehawk Therapeutics stock worth more than $1,118,899 as of July 21st. This net worth approximation does not reflect any other assets that Mr. Giacobello may own. Learn More about Scott M. Giacobello's net worth.
How do I contact Scott M. Giacobello?: The corporate mailing address for Mr. Giacobello and other Whitehawk Therapeutics executives is 17383 SUNSET AVENUE, SUITE A250, PACIFIC PALISADES, CA, 90272. Whitehawk Therapeutics can also be reached via phone at (424) 473-8055 and via email at [email protected]. Learn More on Scott M. Giacobello's contact information.
Has Scott M. Giacobello been buying or selling shares of Whitehawk Therapeutics?: Scott M. Giacobello has not been actively trading shares of Whitehawk Therapeutics over the course of the past ninety days. Most recently, Scott M. Giacobello sold 141,600 shares of the business's stock in a transaction on Thursday, April 16th. The shares were sold at an average price of $4.13, for a transaction totalling $584,808.00. Following the completion of the sale, the chief financial officer now directly owns 295,224 shares of the company's stock, valued at $1,219,275.12. Learn More on Scott M. Giacobello's trading history.
Who are Whitehawk Therapeutics' active insiders?: Whitehawk Therapeutics' insider roster includes Scott Giacobello (CFO), and David Lennon (President & CEO). Learn More on Whitehawk Therapeutics' active insiders.
Are insiders buying or selling shares of Whitehawk Therapeutics?: During the last year, insiders at the sold shares 14 times. They sold a total of 705,358 shares worth more than $2,584,564.00. The most recent insider tranaction occured on April, 16th when CFO Scott M Giacobello sold 141,600 shares worth more than $584,808.00. Insiders at Whitehawk Therapeutics own 49.9% of the company. Learn More about insider trades at Whitehawk Therapeutics.
Information on this page was last updated on 4/16/2026.

Scott M. Giacobello Insider Trading History at Whitehawk Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/16/2026	Sell	141,600	$4.13	$584,808.00	295,224
4/15/2026	Sell	77,000	$3.86	$297,220.00	436,824
3/2/2026	Sell	2,594	$3.31	$8,586.14	28,100

Scott M. Giacobello Buying and Selling Activity at Whitehawk Therapeutics

Whitehawk Therapeutics Company Overview

Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.

Today's Range

Now: $3.85

$3.77

$3.85

50 Day Range

MA: $4.26

$3.79

$5.10

2 Week Range

Now: $3.85

$1.57

$5.49

Volume

45,304 shs

Average Volume

299,924 shs

Market Capitalization

$190.43 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.77